Search

Your search keyword '"Leslie, Lori A."' showing total 428 results
Start Over Author "Leslie, Lori A."
428 results on '"Leslie, Lori A."'

1. Treatment failure patterns in early versus late introduction of CAR T-cell therapy in large B-cell lymphoma

Author

Corona, Magdalena, Ip, Andrew, Brown, Samantha, Luna, Alejandro, Khatib, Hazim, Flynn, Jessica R., Devlin, Sean M., Landego, Ivan, Cassanello, Giulio, Rejeski, Kai, Zuckerman, Tsila, Dahi, Parastoo B., Scordo, Michael, Lin, Richard J., Kabat, Maciej, Luttwak, Efrat, Pavkovic, Emma, Palomba, M. Lia, Park, Jae, Salles, Gilles, Schoder, Heiko, Leithner, Doris, Leslie, Lori A., Perales, Miguel-Angel, Beyar-Katz, Ofrat, Shah, Gunjan L., and Shouval, Roni

Published
2025
Full Text
View/download PDF

2. Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma

Author

Samples, Laura, Sadrzadeh, Hossein, Frigault, Matthew J., Jacobson, Caron A., Hamadani, Mehdi, Gurumurthi, Ashwath, Strati, Paolo, Shouval, Roni, Noy, Ariela, Riedell, Peter A., Dahiya, Saurabh, Maloney, David G., Till, Brian G., Hirayama, Alexandre V., Guathier, Jordan, Gopal, Ajay K., Smith, Stephen D., Poh, Christina, Lynch, Ryan, Ujjani, Chaitra, Di, Mengyang, Raghunathan, Vikram, Shakib-Azar, Mehrdad, Naresh, Kikkeri N., Gooley, Ted A., Yared, Jean, Jain, Michael D., Locke, Frederick L., Leslie, Lori Ann, Epperla, Narendranath, Ghosh, Monalisa, Skarbnik, Alan, Hill, Brian T., Kamdar, Manali K., Ortiz-Maldonado, Valentin, Martinez-Cibrian, Nuria, Shune, Leyla, and Shadman, Mazyar

Published
2025
Full Text
View/download PDF

4. Subsequent Malignancies After CD19-Targeted Chimeric Antigen Receptor T Cells in Patients With Lymphoma

Author

Lorenc, Rachel, Shouval, Roni, Flynn, Jessica R., Devlin, Sean M., Saldia, Amethyst, De Abia, Alejandro Luna, De Lapuerta, Magdalena Corona, Tomas, Ana Alarcon, Cassanello, Giulio, Leslie, Lori A., Rejeski, Kai, Lin, Richard J., Scordo, Michael, Shah, Gunjan L., Palomba, M. Lia, Salles, Gilles, Park, Jae, Giralt, Sergio A., Perales, Miguel-Angel, Ip, Andrew, and Dahi, Parastoo B.

Published
2024
Full Text
View/download PDF

5. Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study

Author

Herrera, Alex F, Zain, Jasmine, Savage, Kerry J, Feldman, Tatyana, Brammer, Jonathan E, Chen, Lu, Puverel, Sandrine, Popplewell, Leslie, Budde, Lihua Elizabeth, Mei, Matthew, Hosing, Chitra, Nair, Ranjit, Leslie, Lori, Daniels, Shari, Peters, Lacolle, Forman, Stephen, Rosen, Steven, Kwak, Larry, and Iyer, Swaminathan P

Published
2024
Full Text
View/download PDF

6. Phase 1/2 study of zilovertamab and ibrutinib in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL).

Author

Lee, Hun Ju, Choi, Michael Y, Siddiqi, Tanya, Rhodes, Joanna Meehan, Wierda, William G, Isufi, Iris, Tuscano, Joseph M, Lamanna, Nicole, Subbiah, Suki, Koff, Jean Louise, Leslie, Lori Ann, Goldenberg, Alec, Chung, Gina G, Yazji, Salim, Wang, Yao, Breitmeyer, James Bradley, Wang, Michael, Jamieson, Catriona, and Kipps, Thomas J

Subjects
Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Published
2022

7. Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)

Author

Neelapu, Sattva S., Chavez, Julio C., Sehgal, Alison R., Epperla, Narendranath, Ulrickson, Matthew, Bachy, Emmanuel, Munshi, Pashna N., Casulo, Carla, Maloney, David G., de Vos, Sven, Reshef, Ran, Leslie, Lori A., Oluwole, Olalekan O., Yakoub-Agha, Ibrahim, Khanal, Rashmi, Rosenblatt, Joseph, Korn, Ronald, Peng, Weixin, Lui, Christine, Wulff, Jacob, Shen, Rhine, Poddar, Soumya, Jung, A. Scott, Miao, Harry, Beygi, Sara, and Jacobson, Caron A.

Published
2024
Full Text
View/download PDF

8. Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma

Author

Scordo, Michael, Flynn, Jessica R., Gonen, Mithat, Devlin, Sean M., Parascondola, Allison, Tomas, Ana Alarcon, Shouval, Roni, Brower, Jamie, Porter, David L., Schuster, Stephen J., Bachanova, Veronika, Maakaron, Joseph, Maziarz, Richard T., Chen, Andy I., Nastoupil, Loretta J., McGuirk, Joseph P., Oluwole, Olalekan O., Ip, Andrew, Leslie, Lori A., Bishop, Michael R., Riedell, Peter A., and Perales, Miguel-Angel

Published
2023
Full Text
View/download PDF

9. Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study

Author

Shadman, Mazyar, Manzoor, Beenish S., Sail, Kavita, Tuncer, Hande H., Allan, John N., Ujjani, Chaitra, Emechebe, Nnadozie, Kamalakar, Rajesh, Coombs, Catherine C., Leslie, Lori, Barr, Paul M., Brown, Jennifer R., Eyre, Toby A., Rampotas, Alexandros, Schuh, Anna, Lamanna, Nicole, Skarbnik, Alan, Roeker, Lindsey E., Bannerji, Rajat, Eichhorst, Barbara, Fleury, Isabelle, Davids, Matthew S., Alhasani, Hasan, Jiang, Dingfeng, Hill, Brian T., Schuster, Stephen J., Brander, Danielle M., Pivneva, Irina, Burne, Rebecca, Guerin, Annie, and Mato, Anthony R.

Published
2023
Full Text
View/download PDF

11. Updates on the Biological Heterogeneity of Mantle Cell Lymphoma.

Author

Ip, Andrew, Kabat, Maciej, Fogel, Lindsay, Alkhatatneh, Hassan, Voss, Jason, Gupta, Amolika, Della Pia, Alexandra, Leslie, Lori A., Feldman, Tatyana, Albitar, Maher, and Goy, Andre H.

Abstract

Simple Summary: This review article provides an update on the current knowledge surrounding mantle cell lymphoma (MCL), focusing on the disease's complexity and heterogeneity, as well as its prognostic factors. Advancements in risk stratification scoring systems are reviewed, and the emerging role of genomic technologies and their potential to inform risk profiling are also highlighted. In addition, the article discusses novel therapies, including Bruton's tyrosine kinase inhibitors, BCL-2 inhibitors, ROR1 inhibitors, and bispecific T-cell engagers, which could become cornerstones of MCL treatment in the future. Advancements in mantle cell lymphoma (MCL) have illuminated the disease's molecular diversity, leading to a wide variation in the outcomes observed in MCL. Current prognostic risk scores are continuously revised to incorporate new updates in the mechanistic or biologic understanding of MCL. Nevertheless, key high-risk features of MCL associated with rapid disease progression and poor survival, such as TP53 mutations, complex karyotypes, and blastoid or pleomorphic morphologies, remain absent from available prognostic tools. The greater accessibility of genomic technologies, such as next-generation sequencing (NGS), has enabled clinicians to identify specific genetic alterations that serve as prognostic signals and disease monitoring parameters, cultivating accurate risk profiling that is illustrative of MCL heterogeneity. Through an increased understanding of distinct MCL behaviors, novel therapies that mechanistically target disease biology, including Bruton's tyrosine kinase inhibitors, BCL-2 inhibitors, ROR1 inhibitors, and bispecific T-cell engagers, have broadened the treatment armamentarium for relapsed/refractory MCL cases. These interventions, in addition to chemoimmunotherapy and autologous stem cell transplantation mainstays, confer the individualization of treatment and improved survival outcomes. Further exploration of the considerable biological heterogeneity of MCL can enhance knowledge, management, and the treatment of this rare lymphoma subtype. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

12. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial

Author

Jacobson, Caron A, Chavez, Julio C, Sehgal, Alison R, William, Basem M, Munoz, Javier, Salles, Gilles, Munshi, Pashna N, Casulo, Carla, Maloney, David G, de Vos, Sven, Reshef, Ran, Leslie, Lori A, Yakoub-Agha, Ibrahim, Oluwole, Olalekan O, Fung, Henry Chi Hang, Rosenblatt, Joseph, Rossi, John M, Goyal, Lovely, Plaks, Vicki, Yang, Yin, Vezan, Remus, Avanzi, Mauro P, and Neelapu, Sattva S

Published
2022
Full Text
View/download PDF

13. Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies

Author

Davids, Matthew S., O'Connor, Owen A., Jurczak, Wojciech, Samaniego, Felipe, Fenske, Timothy S., Zinzani, Pier Luigi, Patel, Manish R., Ghosh, Nilanjan, Cheson, Bruce D., Derenzini, Enrico, Brander, Danielle M., Reeves, James A., Knopińska-Posłuszny, Wanda, Allan, John N., Phillips, Tycel, Caimi, Paolo F., Lech-Maranda, Ewa, Burke, John M., Agajanian, Richy, Pettengell, Ruth, Leslie, Lori A., Cheah, Chan Y., Fonseca, Gustavo, Essell, James, Chavez, Julio C., Pagel, John M., Sharman, Jeff P., Hsu, Yanzhi, Miskin, Hari P., Sportelli, Peter, Weiss, Michael S., and Flinn, Ian W.

Published
2021
Full Text
View/download PDF

14. COVID-19 in patients with CLL: improved survival outcomes and update on management strategies

Author

Roeker, Lindsey E., Eyre, Toby A., Thompson, Meghan C., Lamanna, Nicole, Coltoff, Alexander R., Davids, Matthew S., Baker, Peter O., Leslie, Lori, Rogers, Kerry A., Allan, John N., Cordoba, Raul, Lopez-Garcia, Alberto, Antic, Darko, Pagel, John M., Martinez-Calle, Nicolas, García-Marco, José Antonio, Hernández‐Rivas, Jose‐Ángel, Miras, Fatima, Coombs, Catherine C., Österborg, Anders, Hansson, Lotta, Seddon, Amanda N., López Jiménez, Javier, Wilson, Matthew R., El-Sharkawi, Dima, Wojenski, Daniel, Ma, Shuo, Munir, Talha, Valenciano, Susana, Seymour, Erlene, Barr, Paul M., Pu, Jeffrey, Patten, Piers E.M., Perini, Guilherme F., Huntington, Scott F., Parry, Helen, Sundaram, Suchitra, Skarbnik, Alan, Kamdar, Manali, Jacobs, Ryan, Walter, Harriet, Walewska, Renata, Broom, Angus, Lebowitz, Sonia, Isaac, Krista M., Portell, Craig A., Ahn, Inhye E., Ujjani, Chaitra S., Shadman, Mazyar, Skånland, Sigrid S., Chong, Elise A., and Mato, Anthony R.

Published
2021
Full Text
View/download PDF

16. Outcomes of COVID-19 in patients with CLL: a multicenter international experience

Author

Mato, Anthony R., Roeker, Lindsey E., Lamanna, Nicole, Allan, John N., Leslie, Lori, Pagel, John M., Patel, Krish, Osterborg, Anders, Wojenski, Daniel, Kamdar, Manali, Huntington, Scott F., Davids, Matthew S., Brown, Jennifer R., Antic, Darko, Jacobs, Ryan, Ahn, Inhye E., Pu, Jeffrey, Isaac, Krista M., Barr, Paul M., Ujjani, Chaitra S., Geyer, Mark B., Berman, Ellin, Zelenetz, Andrew D., Malakhov, Nikita, Furman, Richard R., Koropsak, Michael, Bailey, Neil, Hanson, Lotta, Perini, Guilherme F., Ma, Shuo, Ryan, Christine E., Wiestner, Adrian, Portell, Craig A., Shadman, Mazyar, Chong, Elise A., Brander, Danielle M., Sundaram, Suchitra, Seddon, Amanda N., Seymour, Erlene, Patel, Meera, Martinez-Calle, Nicolas, Munir, Talha, Walewska, Renata, Broom, Angus, Walter, Harriet, El-Sharkawi, Dima, Parry, Helen, Wilson, Matthew R., Patten, Piers E.M., Hernández-Rivas, José-Ángel, Miras, Fatima, Fernández Escalada, Noemi, Ghione, Paola, Nabhan, Chadi, Lebowitz, Sonia, Bhavsar, Erica, López-Jiménez, Javier, Naya, Daniel, Garcia-Marco, Jose Antonio, Skånland, Sigrid S., Cordoba, Raul, and Eyre, Toby A.

Published
2020
Full Text
View/download PDF

17. Multicenter, randomized phase II study of epcoritamab for patients with large B-cell lymphomas achieving a partial response after CD19-directed CAR T-cell therapy (CAR-T).

Author

Bock, Allison Marie, primary, Raj, Sandeep, additional, Giri, Sharmila, additional, Leslie, Lori Ann, additional, Patel, Dilan Anil, additional, Iqbal, Madiha, additional, Grover, Natalie Sophia, additional, Hu, Boyu, additional, Perales, Miguel-Angel, additional, and Nowakowski, Grzegorz S., additional

Published
2024
Full Text
View/download PDF

19. Outcomes among adult recipients of CD19 CAR T-cell therapy for Burkitt lymphoma

Author

Samples, Laura, primary, Sadrzadeh, Hossein, additional, Frigault, Matthew, additional, Jacobson, Caron A, additional, Hamadani, Mehdi, additional, Gurumurthi, Ashwath, additional, Strati, Paolo, additional, Shouval, Roni, additional, Riedell, Peter A, additional, Dahiya, Saurab, additional, Yared, Jean, additional, Jain, Michael D, additional, Locke, Frederick, additional, Leslie, Lori A, additional, Epperla, Narendranath, additional, Ghosh, Monalisa, additional, Skarbnik, Alan, additional, Hill, Brian T, additional, Kamdar, Manali K, additional, and Shadman, Mazyar, additional

Published
2023
Full Text
View/download PDF

20. P648: REAL-WORLD TREATMENT AND OUTCOMES OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) RECEIVING FIRST-LINE (1L) THERAPY IN THE NOVEL AGENT ERA: AN INTERNATIONAL STUDY

Author

Lansigan, Frederick, primary, A. Eyre, Toby, additional, Ghosh, Nilanjan, additional, S. Manzoor, Beenish, additional, C. Coombs, Catherine, additional, Lamanna, Nicole, additional, H. Tuncer, Hande, additional, Emechebe, Dozie, additional, R. Brown, Jennifer, additional, E. Roeker, Lindsey, additional, Ujjani, Chaitra, additional, Alhasani, Hasan, additional, Fleury, Isabelle, additional, A. Leslie, Lori, additional, Skarbnik, Alan, additional, Rhodes, Joanna, additional, T. Hill, Brian, additional, M. Barr, Paul, additional, S. Davids, Matthew, additional, P. Fox, Christopher, additional, Choi, Yun, additional, Schuh, Anna, additional, Kennard, Kaitlin, additional, E. Jensen, Christopher, additional, Jawaid, Dureshahwar, additional, Sharma, Aditya, additional, Pivneva, Irina, additional, Watson, Talissa, additional, and Shadman, Mazyar, additional

Published
2023
Full Text
View/download PDF

21. PB2346: ZUMA-24: A PHASE 2, OPEN-LABEL, MULTICENTER STUDY OF AXICABTAGENE CILOLEUCEL IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA GIVEN WITH CORTICOSTEROIDS IN THE OUTPATIENT SETTING

Author

Leslie, Lori, primary, Tees, Michael, additional, Flinn, Ian W., additional, Rodriguez, Tulio, additional, Baird, John H., additional, Deol, Abhinav, additional, Mead, Monica, additional, Bachier, Carlos, additional, Rapoport, Aaron P., additional, Mcclune, Brian, additional, Hoda, Daanish, additional, Perales, Miguel-Angel, additional, Zheng, Yan, additional, Filosto, Simone, additional, Davis1, Madison, additional, Miao, Harry, additional, Kim, Jenny J., additional, and Oluwole, Olalekan O., additional

Published
2023
Full Text
View/download PDF

22. Identifying an Optimal Fludarabine Exposure for Improved Outcomes after CD19 CAR T cell therapy for Aggressive B-NHL

Author

Scordo, Michael, primary, Flynn, Jessica R., additional, Gonen, Mithat, additional, Devlin, Sean M., additional, Parascondola, Allison, additional, Alarcon Tomas, Ana, additional, Shouval, Roni, additional, Brower, Jamie, additional, Porter, David L., additional, Schuster, Stephen J., additional, Bachanova, Veronika, additional, Maakaron, Joseph, additional, Maziarz, Richard T, additional, Chen, Andy I, additional, Nastoupil, Loretta J, additional, McGuirk, Joseph P, additional, Oluwole, Olalekan O., additional, Ip, Andrew, additional, Leslie, Lori A., additional, Bishop, Michael R., additional, Riedell, Peter A., additional, and Perales, Miguel-Angel, additional

Published
2023
Full Text
View/download PDF

23. Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma

Author

Westin, Jason R., primary, Oluwole, Olalekan O., additional, Kersten, Marie José, additional, Miklos, David B., additional, Perales, Miguel-Angel, additional, Ghobadi, Armin, additional, Rapoport, Aaron P., additional, Sureda, Anna, additional, Jacobson, Caron A., additional, Farooq, Umar, additional, van Meerten, Tom, additional, Ulrickson, Matthew, additional, Elsawy, Mahmoud, additional, Leslie, Lori A., additional, Chaganti, Sridhar, additional, Dickinson, Michael, additional, Dorritie, Kathleen, additional, Reagan, Patrick M., additional, McGuirk, Joseph, additional, Song, Kevin W., additional, Riedell, Peter A., additional, Minnema, Monique C., additional, Yang, Yin, additional, Vardhanabhuti, Saran, additional, Filosto, Simone, additional, Cheng, Paul, additional, Shahani, Shilpa A., additional, Schupp, Marco, additional, To, Christina, additional, and Locke, Frederick L., additional

Published
2023
Full Text
View/download PDF

24. Supplementary Figure S4 from Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma

Author

Westin, Jason R., primary, Locke, Frederick L., primary, Dickinson, Michael, primary, Ghobadi, Armin, primary, Elsawy, Mahmoud, primary, van Meerten, Tom, primary, Miklos, David B., primary, Ulrickson, Matthew L., primary, Perales, Miguel-Angel, primary, Farooq, Umar, primary, Wannesson, Luciano, primary, Leslie, Lori, primary, Kersten, Marie José, primary, Jacobson, Caron A., primary, Pagel, John M., primary, Wulf, Gerald, primary, Johnston, Patrick, primary, Rapoport, Aaron P., primary, Du, Linqiu, primary, Vardhanabhuti, Saran, primary, Filosto, Simone, primary, Shah, Jina, primary, Snider, Julia T., primary, Cheng, Paul, primary, To, Christina, primary, Oluwole, Olalekan O., primary, and Sureda, Anna, primary

Published
2023
Full Text
View/download PDF

25. Supplementary Tables S1-S11 from Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma

Author

Westin, Jason R., primary, Locke, Frederick L., primary, Dickinson, Michael, primary, Ghobadi, Armin, primary, Elsawy, Mahmoud, primary, van Meerten, Tom, primary, Miklos, David B., primary, Ulrickson, Matthew L., primary, Perales, Miguel-Angel, primary, Farooq, Umar, primary, Wannesson, Luciano, primary, Leslie, Lori, primary, Kersten, Marie José, primary, Jacobson, Caron A., primary, Pagel, John M., primary, Wulf, Gerald, primary, Johnston, Patrick, primary, Rapoport, Aaron P., primary, Du, Linqiu, primary, Vardhanabhuti, Saran, primary, Filosto, Simone, primary, Shah, Jina, primary, Snider, Julia T., primary, Cheng, Paul, primary, To, Christina, primary, Oluwole, Olalekan O., primary, and Sureda, Anna, primary

Published
2023
Full Text
View/download PDF

26. Data from Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma

Author

Westin, Jason R., primary, Locke, Frederick L., primary, Dickinson, Michael, primary, Ghobadi, Armin, primary, Elsawy, Mahmoud, primary, van Meerten, Tom, primary, Miklos, David B., primary, Ulrickson, Matthew L., primary, Perales, Miguel-Angel, primary, Farooq, Umar, primary, Wannesson, Luciano, primary, Leslie, Lori, primary, Kersten, Marie José, primary, Jacobson, Caron A., primary, Pagel, John M., primary, Wulf, Gerald, primary, Johnston, Patrick, primary, Rapoport, Aaron P., primary, Du, Linqiu, primary, Vardhanabhuti, Saran, primary, Filosto, Simone, primary, Shah, Jina, primary, Snider, Julia T., primary, Cheng, Paul, primary, To, Christina, primary, Oluwole, Olalekan O., primary, and Sureda, Anna, primary

Published
2023
Full Text
View/download PDF

27. Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study

Author

Qualls, David A., Lambert, Nicholas, Caimi, Paolo F., Merrill, Mwanasha, Pullarkat, Priyanka, Godby, Richard C., Bond, David A., Wehmeyer, Graham T., Romancik, Jason, Amoozgar, Behzad, Leslie, Lori, Nastoupil, Loretta J., Crombie, Jennifer L., Abramson, Jeremy S., Khurana, Arushi, Nowakowski, Grzegorz S., Maddocks, Kami, Rutherford, Sarah C., Kahl, Brad, Okwali, Michelle, Buege, Michael J., Seshan, Venkatraman, Batlevi, Connie L., and Salles, Gilles

Published
2023
Full Text
View/download PDF

28. Supplementary Data from Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach

Author

Roeker, Lindsey E., primary, Feldman, Tatyana A., primary, Soumerai, Jacob D., primary, Falco, Victoria, primary, Panton, Gail, primary, Dorsey, Colleen, primary, Zelenetz, Andrew D., primary, Falchi, Lorenzo, primary, Park, Jae H., primary, Straus, David J., primary, Pena Velasquez, Camila, primary, Lebowitz, Sonia, primary, Fox, Yehudit, primary, Battiato, Kristen, primary, Laudati, Carissa, primary, Thompson, Meghan C., primary, McCarthy, Elizabeth, primary, Kdiry, Sabrina, primary, Martignetti, Rosalba, primary, Turpuseema, Teja, primary, Purdom, Michelle, primary, Paskalis, Dana, primary, Miskin, Hari P., primary, Sportelli, Peter, primary, Leslie, Lori A., primary, and Mato, Anthony R., primary

Published
2023
Full Text
View/download PDF

29. Data from Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach

Author

Roeker, Lindsey E., primary, Feldman, Tatyana A., primary, Soumerai, Jacob D., primary, Falco, Victoria, primary, Panton, Gail, primary, Dorsey, Colleen, primary, Zelenetz, Andrew D., primary, Falchi, Lorenzo, primary, Park, Jae H., primary, Straus, David J., primary, Pena Velasquez, Camila, primary, Lebowitz, Sonia, primary, Fox, Yehudit, primary, Battiato, Kristen, primary, Laudati, Carissa, primary, Thompson, Meghan C., primary, McCarthy, Elizabeth, primary, Kdiry, Sabrina, primary, Martignetti, Rosalba, primary, Turpuseema, Teja, primary, Purdom, Michelle, primary, Paskalis, Dana, primary, Miskin, Hari P., primary, Sportelli, Peter, primary, Leslie, Lori A., primary, and Mato, Anthony R., primary

Published
2023
Full Text
View/download PDF

30. Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma

Author

Westin, Jason R., primary, Locke, Frederick L., additional, Dickinson, Michael, additional, Ghobadi, Armin, additional, Elsawy, Mahmoud, additional, van Meerten, Tom, additional, Miklos, David B., additional, Ulrickson, Matthew L., additional, Perales, Miguel-Angel, additional, Farooq, Umar, additional, Wannesson, Luciano, additional, Leslie, Lori, additional, Kersten, Marie José, additional, Jacobson, Caron A., additional, Pagel, John M., additional, Wulf, Gerald, additional, Johnston, Patrick, additional, Rapoport, Aaron P., additional, Du, Linqiu, additional, Vardhanabhuti, Saran, additional, Filosto, Simone, additional, Shah, Jina, additional, Snider, Julia T., additional, Cheng, Paul, additional, To, Christina, additional, Oluwole, Olalekan O., additional, and Sureda, Anna, additional

Published
2023
Full Text
View/download PDF

31. 3-Year Follow-up Analysis of Zuma-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Author

Neelapu, Sattva S., primary, Chavez, Julio C., additional, Sehgal, Alison R., additional, Epperla, Narendranath, additional, Ulrickson, Matthew L., additional, Bachy, Emmanuel, additional, Munshi, Pashna N., additional, Casulo, Carla, additional, Maloney, David G., additional, de Vos, Sven, additional, Reshef, Ran, additional, Leslie, Lori A., additional, Oluwole, Olalekan O., additional, Yakoub-Agha, Ibrahim, additional, Khanal, Rashmi, additional, Rosenblatt, Joseph, additional, Yan, Jiali, additional, Song, Qinghua, additional, Peng, Weixin, additional, Lui, Christine, additional, Wulf, Jacob, additional, Shen, Rhine R., additional, Poddar, Soumya, additional, Miao, Harry, additional, Beygi, Sara, additional, and Jacobson, Caron A., additional

Published
2023
Full Text
View/download PDF

32. Phase 1b dose-finding study of rituximab, lenalidomide, and ibrutinib (R2I) in patients with relapsed/refractory mantle cell lymphoma.

Author

Ip, Andrew, Petrillo, Alessandra, Pia, Alexandra Della, Lee, Geeny G., Gill, Sarvarinder, Varughese, Tony, Zenreich, Joshua, Gutierrez, Martin, Zhang, Jiayu, Ahn, Jaeil, Bharani, Vishnu, Nejad, Ava S., Pascual, Lauren, Feldman, Tatyana A., Leslie, Lori A., and Goy, Andre H.

Subjects
LENALIDOMIDE, RITUXIMAB, NON-Hodgkin's lymphoma, EXANTHEMA
Abstract

Mantle cell lymphoma (MCL) is a rare non-Hodgkin lymphoma that frequently becomes chemoresistant over time. The distinct mechanisms of ibrutinib and lenalidomide provided a judicious rationale to explore the combination with anti-CD20 immunotherapy. In this phase 1b study (NCT02446236), patients (n=25) with relapsed/refractory MCL received rituximab with escalating doses of lenalidomide (days 1–21) and ibrutinib 560mg (days 1–28) of 28-day cycles. The MTD for lenalidomide was 20mg; most common grade ≥3 adverse events were skin rashes (32%) and neutropenic fever (24%). The best ORR was 88%, CR rate was 83%, and median duration of response (DOR) was 36.92months (95% CI 33.77, 51.37). Responses were seen even in refractory patients or with high-risk features (e.g. blastoid variant, TP53 mutation, Ki-67>30%). R2I was safe and tolerable in patients with R/R MCL. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

34. Anti-spike antibody response to the COVID vaccine in lymphoma patients

Author

Della Pia, Alexandra, primary, Kim, Gee Youn (Geeny), additional, Ip, Andrew, additional, Ahn, Jaeil, additional, Liu, Yanzhi, additional, Kats, Simone, additional, Koropsak, Michael, additional, Lukasik, Brittany, additional, Contractor, Anamta, additional, Amin, Krushna, additional, Ayyagari, Lakshmi, additional, Zhao, Charles, additional, Gupta, Amolika, additional, Batistick, Mark, additional, Leslie, Lori A., additional, Goy, Andre H., additional, and Feldman, Tatyana A., additional

Published
2022
Full Text
View/download PDF

35. Dose-Intense Frontline Chemotherapy Changes Molecular Classifier Prognostication in Diffuse Large B-Cell Lymphoma(DLBCL)

Author

Feldman, Tatyana, primary, Albitar, Maher, additional, Cheng, Hong, additional, Chow, Kar, additional, Petrillo, Alessandra, additional, Ulusan, Ahmetmursel, additional, Ip, Andrew, additional, Della Pia, Alexandra, additional, Magarelli, Gabriella, additional, Lukasik, Brittany, additional, Leslie, Lori, additional, Bhattacharyya, Pritish K., additional, Pecora, Andrew L., additional, and Goy, Andre H., additional

Published
2022
Full Text
View/download PDF

36. Subcutaneous Epcoritamab with Rituximab + Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma:Phase 1/2 Trial Update

Author

Falchi, Lorenzo, primary, Abrisqueta, Pau, additional, Nijland, Marcel, additional, Leppä, Sirpa, additional, Hutchings, Martin, additional, Holte, Harald, additional, Merryman, Reid W, additional, Lugtenburg, Pieternella, additional, de Vos, Sven, additional, Cheah, Chan Y., additional, Christensen, Jacob Haaber, additional, Arcaini, Luca, additional, Drott, Kristina, additional, Hellström, Mats, additional, Leslie, Lori A., additional, Vitolo, Umberto, additional, Rana, Ali, additional, Abbas, Aqeel, additional, Wang, Liwei, additional, Dinh, Minh, additional, and Belada, David, additional

Published
2022
Full Text
View/download PDF

37. 3-Year Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Author

Neelapu, Sattva S., primary, Chavez, Julio, additional, Sehgal, Alison R., additional, Epperla, Narendranath, additional, Ulrickson, Matthew, additional, Bachy, Emanuel, additional, Munshi, Pashna N., additional, Casulo, Carla, additional, Maloney, David G., additional, de Vos, Sven, additional, Reshef, Ran, additional, Leslie, Lori A., additional, Oluwole, Olalekan O., additional, Yakoub-Agha, Ibrahim, additional, Khanal, Rashmi, additional, Rosenblatt, Joseph D., additional, Yan, Jiali, additional, Song, Qinghua, additional, Peng, Weixin, additional, Lui, Christine, additional, Wulff, Jacob, additional, Shen, Rhine R., additional, Poddar, Soumya, additional, Miao, Harry, additional, Beygi, Sara, additional, and Jacobson, Caron A., additional

Published
2022
Full Text
View/download PDF

38. Population Pharmacokinetic Model Identifies an Optimal Fludarabine Exposure for Improved Outcomes after CD19-Directed CAR T Cell Therapy for Aggressive B-NHL: Analysis from the Cell Therapy Consortium

Author

Scordo, Michael, primary, Flynn, Jessica R., additional, Devlin, Sean M., additional, Gonen, Mithat, additional, Parascondola, Allison, additional, Alarcon Tomas, Ana, additional, Shouval, Roni, additional, Brower, Jamie, additional, Porter, David L., additional, Schuster, Stephen J., additional, Bachanova, Veronika, additional, Maakaron, Joseph E., additional, Maziarz, Richard T., additional, Nastoupil, Loretta J., additional, McGuirk, Joseph P., additional, Oluwole, Olalekan O., additional, Ip, Andrew, additional, Leslie, Lori A., additional, Bishop, Michael R., additional, Riedell, Peter A., additional, and Perales, Miguel-Angel, additional

Published
2022
Full Text
View/download PDF

39. Tafasitamab and Lenalidomide in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL): Real World Outcomes in a Multicenter Retrospective Study

Author

Qualls, David, primary, Buege, Michael J, additional, Dao, Phuong, additional, Caimi, Paolo F., additional, Rutherford, Sarah C., additional, Wehmeyer, Graham, additional, Romancik, Jason T., additional, Leslie, Lori A., additional, Merrill, Mwanasha H., additional, Crombie, Jennifer L., additional, Amoozgar, Behzad, additional, Kahl, Brad S., additional, Bond, David A., additional, Maddocks, Kami J., additional, Okwali, Michelle, additional, Seshan, Venkatraman, additional, Salles, Gilles, additional, and Batlevi, Connie Lee, additional

Published
2022
Full Text
View/download PDF

40. Subcutaneous Epcoritamab in Combination with Rituximab + Lenalidomide (R2) for First-Line Treatment of Follicular Lymphoma: Initial Results from Phase 1/2 Trial

Author

Falchi, Lorenzo, primary, Leslie, Lori A., additional, Belada, David, additional, Kopeckova, Katerina, additional, Offner, Fritz, additional, Brody, Joshua, additional, Canales, Miguel, additional, Martín García-Sancho, Alejandro, additional, Nijland, Marcel, additional, Andersson, P-O, additional, Awan, Farrukh T., additional, Christensen, Jacob Haaber, additional, Drott, Kristina, additional, Hellström, Mats, additional, Lewerin, Catharina, additional, Narkhede, Mayur, additional, Snauwaert, Sylvia, additional, Wahlin, Björn E, additional, Rana, Ali, additional, Abbas, Aqeel, additional, Wang, Liwei, additional, Dinh, Minh, additional, Vermaat, Joost S.P., additional, and Abrisqueta, Pau, additional

Published
2022
Full Text
View/download PDF

41. Phase 1/2 Study of Zilovertamab and Ibrutinib in Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), or Marginal Zone Lymphoma (MZL)

Author

Lee, Hun Ju, primary, Choi, Michael Y., additional, Siddiqi, Tanya, additional, Rhodes, Joanna M., additional, Wierda, William G., additional, Isufi, Iris, additional, Tuscano, Joseph M, additional, Lamanna, Nicole, additional, Subbiah, Suki, additional, Koff, Jean L., additional, Leslie, Lori, additional, Goldenberg, Alec, additional, Chung, Gina G, additional, Breitmeyer, James B., additional, Yazji, Salim, additional, Wang, Michael, additional, Jamieson, Catriona, additional, and Kipps, Thomas J., additional

Published
2022
Full Text
View/download PDF

43. CTIM-34. PRELIMINARY SAFETY AND EFFICACY DATA ON TWO PATIENTS WITH RELAPSED/REFRACTORY CNS LYMPHOMA TREATED WITH EMAVUSERTIB (CA-4948) AND IBRUTINIB COMBINATION: A SUBSET ANALYSIS OF TAKEAIM LYMPHOMA TRIAL

Author

Iqbal, Madiha, primary, Tun, Han, additional, Joffe, Erel, additional, Grommes, Christian, additional, Nowakowski, Grzegorz, additional, Lunning, Matthew, additional, Ramchandren, Radhakrishnan, additional, Li, Chia-Cheng, additional, Zhao, Wanying, additional, Martinez, Elizabeth, additional, von Roemeling, Reinhard, additional, Earhart, Robert, additional, McMahon, Meaghan, additional, Isufi, Iris, additional, Leslie, Lori, additional, and Rosenthal, Allison, additional

Published
2022
Full Text
View/download PDF

45. Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase 2 Study of an MRD-driven Approach

Author

Roeker, Lindsey E., Feldman, Tatyana A., Soumerai, Jacob D., Falco, Victoria, Panton, Gail, Dorsey, Colleen, Zelenetz, Andrew D., Falchi, Lorenzo, Park, Jae H., Straus, David J., Velasquez, Camila Pena, Lebowitz, Sonia, Fox, Yehudit, Battiato, Kristen, Laudati, Carissa, Thompson, Meghan C., McCarthy, Elizabeth, Kdiry, Sabrina, Martignetti, Rosalba, Turpuseema, Teja, Purdom, Michelle, Paskalis, Dana, Miskin, Hari P., Sportelli, Peter, Leslie, Lori A., and Mato, Anthony R.

Subjects
Neoplasm, Residual, Piperidines, Adenine, Antineoplastic Combined Chemotherapy Protocols, Antibodies, Monoclonal, Humans, Heterocyclic Compounds, 4 or More Rings, Leukemia, Lymphocytic, Chronic, B-Cell, Article
Abstract

Ibrutinib has transformed the management of chronic lymphocytic leukemia (CLL), though its use is limited by toxicity and resistance. In this study, we utilized an "add on" approach for patients who had been treated with ibrutinib in the front-line or relapsed/refractory settings with detectable MRD. Umbralisib and ublituximab (U2) were added on to ibrutinib, patients were treated until achieving undetectable-MRD (U-MRD), and then they entered a period of treatment-free observation (TFO).Patients were eligible if they received ibrutinib in any line of therapy for at least 6 months and had detectable MRD (flow cytometry,1 cell in 10-4 cutoff for U-MRD). U2 was added to ibrutinib, and patients were monitored serially for MRD. Once U-MRD was achieved or a total of 24 cycles were administered, patients entered a period of TFO. The primary study objective was rate of U-MRD. Secondary endpoints included safety and durability of clinical benefit after treatment discontinuation.Twenty-eight patients were enrolled of whom 27 were evaluable for efficacy. Patients received ibrutinib for a median of 21 months (range 7-67) prior to study enrollment. Fourteen patients (52%) have achieved U-MRD per protocol whereas 78% had at least one U-MRD evaluation. Seventeen patients (63%) have entered TFO after a median of 6.4 months on triplet therapy. Progression-free survival at 12 months was estimated at 95%. Grade ≥3 adverse events were hypertension 7%, diarrhea 4%, and increased ALT/AST 4%.This triplet approach utilizes the addition of U2 to ibrutinib as an MRD-driven time-limited therapy. This therapy was well tolerated and effective. TFO following this therapy appears durable in ongoing follow-up.

Published
2022

46. Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen

Author

Thompson, Meghan C., Harrup, Rosemary A., Coombs, Catherine C., Roeker, Lindsey E., Pu, Jeffrey J., Choi, Michael Y., Barr, Paul M., Allan, John N., Šimkovič, Martin, Leslie, Lori, Rhodes, Joanna, Chong, Elise A., Kamdar, Manali, Skarbnik, Alan, Lansigan, Frederick, McCall, Brittany, Saja, Khalid, Dyer, Martin J.S., Walter, Harriet S., Lefebure, Marcus, Thadani-Mulero, Maria, Boyer, Michelle, Biondo, Juliana, Sail, Kavita, Manzoor, Beenish S., Furman, Richard, Bantilan, Kurt S., Goy, Andre, Feldman, Tatyana, Labella, Dominic, Schuster, Stephen J., Park, Jae, Palomba, Lia, Zelenetz, Andrew, Eyre, Toby A., Kater, Arnon P., Seymour, John F., and Mato, Anthony R.

Published
2022
Full Text
View/download PDF

47. Improved Survival of Lymphoma Patients with COVID-19 in the Modern Treatment and Vaccination Era

Author

Della Pia, Alexandra, primary, Zhao, Charles, additional, Jandir, Parul, additional, Gupta, Amolika, additional, Batistick, Mark, additional, Kim, Gee Youn (Geeny), additional, Xia, Yi, additional, Ahn, Jaeil, additional, Magarelli, Gabriella, additional, Lukasik, Brittany, additional, Leslie, Lori A., additional, Goy, Andre H., additional, Ip, Andrew, additional, and Feldman, Tatyana A., additional

Published
2022
Full Text
View/download PDF

48. Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach

Author

Roeker, Lindsey E., primary, Feldman, Tatyana A., additional, Soumerai, Jacob D., additional, Falco, Victoria, additional, Panton, Gail, additional, Dorsey, Colleen, additional, Zelenetz, Andrew D., additional, Falchi, Lorenzo, additional, Park, Jae H., additional, Straus, David J., additional, Pena Velasquez, Camila, additional, Lebowitz, Sonia, additional, Fox, Yehudit, additional, Battiato, Kristen, additional, Laudati, Carissa, additional, Thompson, Meghan C., additional, McCarthy, Elizabeth, additional, Kdiry, Sabrina, additional, Martignetti, Rosalba, additional, Turpuseema, Teja, additional, Purdom, Michelle, additional, Paskalis, Dana, additional, Miskin, Hari P., additional, Sportelli, Peter, additional, Leslie, Lori A., additional, and Mato, Anthony R., additional

Published
2022
Full Text
View/download PDF

50. CLL-495 Treatment Characteristics and Outcomes of Patients With Chronic/Small Lymphocytic Leukemia (CLL) Treated With Venetoclax and Bruton Tyrosine Kinase Inhibitor (BTKi) Combination Therapies

Author

Tuncer, Hande H., Ghosh, Nilanjan, Fleury, Isabelle, Leslie, Lori A., Manzoor, Beenish S., Lamanna, Nicole, Eyre, Toby A., Hill, Brian T., Brown, Jennifer R., Sinai, Wendy, Coombs, Catherine C., Ujjani, Chaitra, Roeker, Lindsey E., Emechebe, Nnadozie, Barr, Paul M., Davids, Matthew S., Martinez-Calle, Nicolas, Rhodes, Joanna M., Lansigan, Frederick, Pearson, Laurie, Choi, Yun, Schuster, Stephen J., Skarbnik, Alan P., Fakhri, Bita, Coyle, Michael, Stephens, Deborah M., Thompson, Meghan C., Jensen, Christopher E., Marx, Steven E., Jawaid, Dureshahwar, Schuh, Anna, Pivneva, Irina, Watson, Talissa, Guerin, Annie, and Shadman, Mazyar

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results